Mitochondrial dysfunction and liver disease: role, relevance, and potential for therapeutic modulation
Author(s)
Middleton, Paul
Vergis, Nikhil
Type
Journal Article
Abstract
Mitochondria are key organelles involved in energy production as well as numerous metabolic processes. There is a growing interest in the role of mitochondrial dysfunction in the pathogenesis of common chronic diseases as well as in cancer development. This review will examine the role mitochondria play in the pathophysiology of common liver diseases, including alcohol-related liver disease, non-alcoholic fatty liver disease, chronic hepatitis B and hepatocellular carcinoma. Mitochondrial dysfunction is described widely in the literature in studies examining patient tissue and in disease models. Despite significant differences in pathophysiology between chronic liver diseases, common mitochondrial defects are described, including increased mitochondrial reactive oxygen species production and impaired oxidative phosphorylation. We review the current literature on mitochondrial-targeted therapies, which have the potential to open new therapeutic avenues in the management of patients with chronic liver disease.
Date Issued
2021-07-27
Date Acceptance
2021-06-18
Citation
Therapeutic Advances in Gastroenterology, 2021, 14, pp.1-19
ISSN
1756-2848
Publisher
SAGE Publications
Start Page
1
End Page
19
Journal / Book Title
Therapeutic Advances in Gastroenterology
Volume
14
Copyright Statement
© The Author(s), 2021.
Article reuse guidelines:
sagepub.com/journalspermissions. This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Article reuse guidelines:
sagepub.com/journalspermissions. This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
License URL
Sponsor
Medical Research Council (MRC)
Wellcome Trust ISSF
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000687999700001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Grant Number
MR/R014019/1
294834/Z/16/Z ISSF ICL
Subjects
Science & Technology
Life Sciences & Biomedicine
Gastroenterology & Hepatology
alcohol related liver disease (ALD)
hepatitis B
hepatocellular carcinoma (HCC)
liver disease
mitochondria
non-alcoholic fatty liver disease (NAFLD)
VIRUS-X PROTEIN
NONALCOHOLIC-FATTY-LIVER
PERMEABILITY TRANSITION PORE
ALDEHYDE DEHYDROGENASE 2
HEPATIC MITOCHONDRIAL
HEPATOCELLULAR-CARCINOMA
OXIDATIVE STRESS
UNCOUPLING PROTEIN-2
RESPIRATORY-CHAIN
INDUCED APOPTOSIS
Publication Status
Published
Article Number
ARTN 17562848211031394
Date Publish Online
2021-07-27